In this @latimes op-ed, @ISBNathanPrice & I talk about new Alzheimer’s disease drugs, and how their efficacy is contested while the potential of prevention is untapped and underreported. latimes.com/opinion/story/…
www.latimes.com Opinion: New Alzheimer's drugs are costly and controversial. Are we going about this all wrong? New medications such as lecanemab offer at best modest effects and major expenses. But dementia can be forestalled with practical and affordable measures. 